Role of bradykinin in renoprotective effects by angiotensin II type 1 receptor antagonist in salt-sensitive hypertension

Kazuaki Yokota, Masayuki Kishida, Toshio Ogura, Jiro Suzuki, Fumio Otsuka, Yukari Mimura, Masaya Takeda, Yoshio Nakamura, Hirofumi Makino

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

To elucidate whether bradykinin is involved in the renoprotective effect produced by angiotensin II type 1 receptor antagonist (AT1A) in chronic salt-sensitive hypertension, Dahl salt-sensitive rats receiving a high-salt (8%) diet were treated either with an AT1A (candesartan, 1 mg/kg/day), a bradykinin B2 receptor antagonist (BKB2A; FR172357, 30 mg/kg/day) or a combination of AT1A and BKB2A for 7 weeks. None of the treatments changed the markedly increased systolic blood pressure induced by a high-salt diet. However, chronic treatment with AT1A significantly improved the histological hallmarks of renal damage - i.e., glomerular sclerosis and cell proliferation - despite the presence of severe hypertension. This beneficial action of AT1A was abolished by the concomitant administration of BKB2A. In agreement with these histologically based findings, increases in levels of creatinine clearance induced by AT1A were also reversed back to the basal levels when BKB2A was administered in conjunction with AT1A. Furthermore, urinary excretions of nitrate plus nitrite and prostaglandin E2 increased moderately in response to the administration of AT1A alone, but not in combination with BKB2A. Thus, the blockade of bradykinin signaling abrogates the renoprotective actions of the angiotensin II type 1 (AT1) receptor antagonism. Collectively, these data show that when AT1 action is chronically blocked, endogenous bradykinin plays a pivotal role in preventing the progression of glomerular injury in salt-sensitive hypertension.

Original languageEnglish
Pages (from-to)265-272
Number of pages8
JournalHypertension Research
Volume26
Issue number3
DOIs
Publication statusPublished - Mar 2003

Fingerprint

Angiotensin II Type 1 Receptor Blockers
Bradykinin
Salts
Hypertension
Inbred Dahl Rats
Diet
Blood Pressure
Angiotensin Type 1 Receptor
Sclerosis
Nitrites
Dinoprostone
Angiotensin II
Nitrates
Creatinine
Cell Proliferation
Kidney
Wounds and Injuries

Keywords

  • Angiotensin II type 1 and 2 receptors
  • Bradykinin
  • Glomerulus
  • Nitric oxide
  • Prostaglandins

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Role of bradykinin in renoprotective effects by angiotensin II type 1 receptor antagonist in salt-sensitive hypertension. / Yokota, Kazuaki; Kishida, Masayuki; Ogura, Toshio; Suzuki, Jiro; Otsuka, Fumio; Mimura, Yukari; Takeda, Masaya; Nakamura, Yoshio; Makino, Hirofumi.

In: Hypertension Research, Vol. 26, No. 3, 03.2003, p. 265-272.

Research output: Contribution to journalArticle

Yokota, Kazuaki ; Kishida, Masayuki ; Ogura, Toshio ; Suzuki, Jiro ; Otsuka, Fumio ; Mimura, Yukari ; Takeda, Masaya ; Nakamura, Yoshio ; Makino, Hirofumi. / Role of bradykinin in renoprotective effects by angiotensin II type 1 receptor antagonist in salt-sensitive hypertension. In: Hypertension Research. 2003 ; Vol. 26, No. 3. pp. 265-272.
@article{53f34eac57b445a1b13de2aef42e4016,
title = "Role of bradykinin in renoprotective effects by angiotensin II type 1 receptor antagonist in salt-sensitive hypertension",
abstract = "To elucidate whether bradykinin is involved in the renoprotective effect produced by angiotensin II type 1 receptor antagonist (AT1A) in chronic salt-sensitive hypertension, Dahl salt-sensitive rats receiving a high-salt (8{\%}) diet were treated either with an AT1A (candesartan, 1 mg/kg/day), a bradykinin B2 receptor antagonist (BKB2A; FR172357, 30 mg/kg/day) or a combination of AT1A and BKB2A for 7 weeks. None of the treatments changed the markedly increased systolic blood pressure induced by a high-salt diet. However, chronic treatment with AT1A significantly improved the histological hallmarks of renal damage - i.e., glomerular sclerosis and cell proliferation - despite the presence of severe hypertension. This beneficial action of AT1A was abolished by the concomitant administration of BKB2A. In agreement with these histologically based findings, increases in levels of creatinine clearance induced by AT1A were also reversed back to the basal levels when BKB2A was administered in conjunction with AT1A. Furthermore, urinary excretions of nitrate plus nitrite and prostaglandin E2 increased moderately in response to the administration of AT1A alone, but not in combination with BKB2A. Thus, the blockade of bradykinin signaling abrogates the renoprotective actions of the angiotensin II type 1 (AT1) receptor antagonism. Collectively, these data show that when AT1 action is chronically blocked, endogenous bradykinin plays a pivotal role in preventing the progression of glomerular injury in salt-sensitive hypertension.",
keywords = "Angiotensin II type 1 and 2 receptors, Bradykinin, Glomerulus, Nitric oxide, Prostaglandins",
author = "Kazuaki Yokota and Masayuki Kishida and Toshio Ogura and Jiro Suzuki and Fumio Otsuka and Yukari Mimura and Masaya Takeda and Yoshio Nakamura and Hirofumi Makino",
year = "2003",
month = "3",
doi = "10.1291/hypres.26.265",
language = "English",
volume = "26",
pages = "265--272",
journal = "Hypertension Research",
issn = "0916-9636",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Role of bradykinin in renoprotective effects by angiotensin II type 1 receptor antagonist in salt-sensitive hypertension

AU - Yokota, Kazuaki

AU - Kishida, Masayuki

AU - Ogura, Toshio

AU - Suzuki, Jiro

AU - Otsuka, Fumio

AU - Mimura, Yukari

AU - Takeda, Masaya

AU - Nakamura, Yoshio

AU - Makino, Hirofumi

PY - 2003/3

Y1 - 2003/3

N2 - To elucidate whether bradykinin is involved in the renoprotective effect produced by angiotensin II type 1 receptor antagonist (AT1A) in chronic salt-sensitive hypertension, Dahl salt-sensitive rats receiving a high-salt (8%) diet were treated either with an AT1A (candesartan, 1 mg/kg/day), a bradykinin B2 receptor antagonist (BKB2A; FR172357, 30 mg/kg/day) or a combination of AT1A and BKB2A for 7 weeks. None of the treatments changed the markedly increased systolic blood pressure induced by a high-salt diet. However, chronic treatment with AT1A significantly improved the histological hallmarks of renal damage - i.e., glomerular sclerosis and cell proliferation - despite the presence of severe hypertension. This beneficial action of AT1A was abolished by the concomitant administration of BKB2A. In agreement with these histologically based findings, increases in levels of creatinine clearance induced by AT1A were also reversed back to the basal levels when BKB2A was administered in conjunction with AT1A. Furthermore, urinary excretions of nitrate plus nitrite and prostaglandin E2 increased moderately in response to the administration of AT1A alone, but not in combination with BKB2A. Thus, the blockade of bradykinin signaling abrogates the renoprotective actions of the angiotensin II type 1 (AT1) receptor antagonism. Collectively, these data show that when AT1 action is chronically blocked, endogenous bradykinin plays a pivotal role in preventing the progression of glomerular injury in salt-sensitive hypertension.

AB - To elucidate whether bradykinin is involved in the renoprotective effect produced by angiotensin II type 1 receptor antagonist (AT1A) in chronic salt-sensitive hypertension, Dahl salt-sensitive rats receiving a high-salt (8%) diet were treated either with an AT1A (candesartan, 1 mg/kg/day), a bradykinin B2 receptor antagonist (BKB2A; FR172357, 30 mg/kg/day) or a combination of AT1A and BKB2A for 7 weeks. None of the treatments changed the markedly increased systolic blood pressure induced by a high-salt diet. However, chronic treatment with AT1A significantly improved the histological hallmarks of renal damage - i.e., glomerular sclerosis and cell proliferation - despite the presence of severe hypertension. This beneficial action of AT1A was abolished by the concomitant administration of BKB2A. In agreement with these histologically based findings, increases in levels of creatinine clearance induced by AT1A were also reversed back to the basal levels when BKB2A was administered in conjunction with AT1A. Furthermore, urinary excretions of nitrate plus nitrite and prostaglandin E2 increased moderately in response to the administration of AT1A alone, but not in combination with BKB2A. Thus, the blockade of bradykinin signaling abrogates the renoprotective actions of the angiotensin II type 1 (AT1) receptor antagonism. Collectively, these data show that when AT1 action is chronically blocked, endogenous bradykinin plays a pivotal role in preventing the progression of glomerular injury in salt-sensitive hypertension.

KW - Angiotensin II type 1 and 2 receptors

KW - Bradykinin

KW - Glomerulus

KW - Nitric oxide

KW - Prostaglandins

UR - http://www.scopus.com/inward/record.url?scp=0037360013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037360013&partnerID=8YFLogxK

U2 - 10.1291/hypres.26.265

DO - 10.1291/hypres.26.265

M3 - Article

C2 - 12675283

AN - SCOPUS:0037360013

VL - 26

SP - 265

EP - 272

JO - Hypertension Research

JF - Hypertension Research

SN - 0916-9636

IS - 3

ER -